{"protocolSection":{"identificationModule":{"nctId":"NCT05274269","orgStudyIdInfo":{"id":"VX21-445-124"},"secondaryIdInfos":[{"id":"2021-005320-38","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Vertex Pharmaceuticals Incorporated","class":"INDUSTRY"},"briefTitle":"Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation","officialTitle":"A Phase 3 Double-blind, Randomized, Placebo-controlled Study Evaluating the Efficacy and Safety of ELX/TEZ/IVA in Cystic Fibrosis Subjects 6 Years of Age and Older With a Non-F508del ELX/TEZ/IVA-responsive CFTR Mutation"},"statusModule":{"statusVerifiedDate":"2024-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-05-09","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-07-05","type":"ACTUAL"},"completionDateStruct":{"date":"2023-07-05","type":"ACTUAL"},"studyFirstSubmitDate":"2022-03-01","studyFirstSubmitQcDate":"2022-03-01","studyFirstPostDateStruct":{"date":"2022-03-10","type":"ACTUAL"},"resultsFirstSubmitDate":"2024-07-03","resultsFirstSubmitQcDate":"2024-07-31","resultsFirstPostDateStruct":{"date":"2024-08-01","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-07-31","lastUpdatePostDateStruct":{"date":"2024-08-01","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Vertex Pharmaceuticals Incorporated","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"This study evaluated the efficacy, pharmacodynamics (PD) and safety of ELX/TEZ/IVA in participants 6 years of age and older with a non-F508del ELX/TEZ/IVA-responsive cystic fibrosis transmembrane conductance regulator gene (CFTR) mutation."},"conditionsModule":{"conditions":["Cystic Fibrosis"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":307,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Participants received placebo matched to ELX/TEZ/IVA FDC in the morning and placebo matched to IVA in the evening for 24 weeks.","interventionNames":["Other: Placebo (matched to ELX/TEZ/IVA)","Other: Placebo (matched to IVA)"]},{"label":"ELX/TEZ/IVA","type":"EXPERIMENTAL","description":"Participants 6 to less than (\\<) 12 years of age and weighing \\<30 kilogram (kg) at Day 1 received ELX 100 milligram (mg)/TEZ 50 mg /IVA 75 mg as fixed dose combination (FDC) tablets in the morning and IVA as mono tablet in the evening and those weighing more than or equal to (≥) 30 kg at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks. Participants ≥12 years age at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks.","interventionNames":["Drug: ELX/TEZ/IVA","Drug: IVA"]}],"interventions":[{"type":"DRUG","name":"ELX/TEZ/IVA","description":"Fixed-dose combination (FDC) tablets for oral administration.","armGroupLabels":["ELX/TEZ/IVA"],"otherNames":["VX-445/VX-661/VX-770","elexacaftor/tezacaftor/ivacaftor"]},{"type":"DRUG","name":"IVA","description":"Tablet for oral administration.","armGroupLabels":["ELX/TEZ/IVA"],"otherNames":["VX-770","ivacaftor"]},{"type":"OTHER","name":"Placebo (matched to ELX/TEZ/IVA)","description":"Placebo matched to ELX/TEZ/IVA for oral administration.","armGroupLabels":["Placebo"]},{"type":"OTHER","name":"Placebo (matched to IVA)","description":"Placebo matched to IVA for oral administration.","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)","description":"FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.","timeFrame":"From Baseline Through Week 24"}],"secondaryOutcomes":[{"measure":"Absolute Change in Sweat Chloride (SwCl)","description":"Sweat samples were collected using an approved collection device.","timeFrame":"From Baseline Through Week 24"},{"measure":"Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain (RD) Score","description":"The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.","timeFrame":"From Baseline Through Week 24"},{"measure":"Absolute Change in Body Mass Index (BMI)","description":"BMI was defined as weight in kilogram (kg) divided by height in square meter (m\\^2).","timeFrame":"From Baseline at Week 24"},{"measure":"Absolute Change in Weight","timeFrame":"From Baseline at Week 24"},{"measure":"Number of Pulmonary Exacerbations (PEx)","description":"Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.","timeFrame":"From Baseline Through Week 24"},{"measure":"Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"Day 1 up to Week 28"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Participant has a qualifying ELX/TEZ/IVA-responsive CFTR mutation and does not have an exclusionary CFTR mutation\n* Forced expiratory volume in 1 second (FEV1) value \\>=40% and \\<=100% of predicted mean for age, sex, and height\n\nKey Exclusion Criteria:\n\n* History of solid organ or hematological transplantation\n* Clinically significant cirrhosis with or without portal hypertension\n* Lung infection with organisms associated with a more rapid decline in pulmonary status\n\nOther protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Medizinische Universität Innsbruck","city":"Innsbruck","country":"Austria","geoPoint":{"lat":47.26266,"lon":11.39454}},{"facility":"Cliniques Universitaires de Bruxelles Hopital Erasme","city":"Brussels","country":"Belgium","geoPoint":{"lat":50.85045,"lon":4.34878}},{"facility":"Universitair Ziekenhuis Brussel - Campus Jette","city":"Brussels","country":"Belgium","geoPoint":{"lat":50.85045,"lon":4.34878}},{"facility":"Universitair Ziekenhuis Antwerpen (UZA) - Antwerp University Hospital","city":"Edegem","country":"Belgium","geoPoint":{"lat":51.15662,"lon":4.44504}},{"facility":"Universitair Ziekenhuis Gent","city":"Gent","country":"Belgium","geoPoint":{"lat":51.05,"lon":3.71667}},{"facility":"Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg","city":"Leuven","country":"Belgium","geoPoint":{"lat":50.87959,"lon":4.70093}},{"facility":"Cliniques Universitaires Saint-Luc","city":"Woluwe-Saint-Lambert","country":"Belgium","geoPoint":{"lat":50.84389,"lon":4.42912}},{"facility":"Stollery Children's Hospital","city":"Edmonton","country":"Canada","geoPoint":{"lat":53.55014,"lon":-113.46871}},{"facility":"Centre Hospitalier de l'Universite de Montreal (CHUM) Hotel-Dieu","city":"Montreal","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"McGill University Health Centre, Glen Site, Montreal Children's Hospital","city":"Montreal","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"The Hospital for Sick Children","city":"Toronto","country":"Canada","geoPoint":{"lat":43.70011,"lon":-79.4163}},{"facility":"British Columbia Children's Hospital","city":"Vancouver","country":"Canada","geoPoint":{"lat":49.24966,"lon":-123.11934}},{"facility":"St. Paul's Hospital","city":"Vancouver","country":"Canada","geoPoint":{"lat":49.24966,"lon":-123.11934}},{"facility":"Klinika Detskych Infekcnich Nemoci","city":"Brno","country":"Czechia","geoPoint":{"lat":49.19522,"lon":16.60796}},{"facility":"Fakultni nemocnice v Motole","city":"Praha 5","country":"Czechia","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"CHU Lyon - Hopital Femme Mere-Enfant","city":"Bron Cedex","country":"France","geoPoint":{"lat":45.73333,"lon":4.91667}},{"facility":"Centre Hospitalier Intercommunal Creteil","city":"Créteil","country":"France","geoPoint":{"lat":48.78333,"lon":2.46667}},{"facility":"Institut Cœur Poumon, CHU de Lille","city":"Lille","country":"France","geoPoint":{"lat":50.63297,"lon":3.05858}},{"facility":"CHU Marseille - Hopital Nord","city":"Marseille","country":"France","geoPoint":{"lat":43.29551,"lon":5.38958}},{"facility":"Hopital Arnaud de Villeneuve","city":"Montpellier Cedex 5","country":"France","geoPoint":{"lat":43.61092,"lon":3.87723}},{"facility":"Centre Hospitalier Universitaire De Nantes - G. R. Laennec","city":"Nantes","country":"France","geoPoint":{"lat":47.21725,"lon":-1.55336}},{"facility":"Centre Hospitalier Universitaire (CHU) de Nice - Hopital Pasteur","city":"Nice","country":"France","geoPoint":{"lat":43.70313,"lon":7.26608}},{"facility":"Hopital Necker, Enfants Malades","city":"Paris Cedex 15","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Hopital Cochin","city":"Paris","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Hopital Robert Debre","city":"Paris","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Hopital Haut-Leveque - CRCM Adulte","city":"Pessac","country":"France","geoPoint":{"lat":44.81011,"lon":-0.64129}},{"facility":"Centre Hospitalier Lyon Sud","city":"Pierre-Bénite","country":"France","geoPoint":{"lat":45.7009,"lon":4.82511}},{"facility":"Centre Hospitalier Universitaire De Reims, Hopital Sebastopol","city":"Reims","country":"France","geoPoint":{"lat":49.25,"lon":4.03333}},{"facility":"CHU de Rennes - Hôpital Sud","city":"Rennes","country":"France","geoPoint":{"lat":48.11198,"lon":-1.67429}},{"facility":"Centre de Perharidy","city":"Roscoff Cedex","country":"France","geoPoint":{"lat":48.72381,"lon":-3.98709}},{"facility":"CHU de Toulouse - Hopital Larre","city":"Toulouse","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"facility":"Hopital Bretonneau","city":"Tours","country":"France","geoPoint":{"lat":47.38333,"lon":0.68333}},{"facility":"Charite Paediatric Pulmonology Department","city":"Berlin","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Friedrich-Alexander University of Erlangen-Nuremberg, University Children's Hospital","city":"Erlangen","country":"Germany","geoPoint":{"lat":49.59099,"lon":11.00783}},{"facility":"Ruhrlandklinik Westdeutsches Lungenzentrum am Klinikum Essen","city":"Essen","country":"Germany","geoPoint":{"lat":51.45657,"lon":7.01228}},{"facility":"Johann Wolfgang Goethe University","city":"Frankfurt","country":"Germany","geoPoint":{"lat":50.11552,"lon":8.68417}},{"facility":"Justus-Liebig-Universität Gießen Zentrum für Kinderheilkunde und Jugendmedizin","city":"Gießen","country":"Germany","geoPoint":{"lat":50.58727,"lon":8.67554}},{"facility":"Universitätsklinikum Halle (Saale) / Universitätsklinik und Poliklinik für Innere Medizin, Schwerpunkt Pneumologie","city":"Halle","country":"Germany","geoPoint":{"lat":51.48159,"lon":11.97948}},{"facility":"Hannover Medical School","city":"Hannover","country":"Germany","geoPoint":{"lat":52.37052,"lon":9.73322}},{"facility":"Medizinische Hochschule Hannover","city":"Hannover","country":"Germany","geoPoint":{"lat":52.37052,"lon":9.73322}},{"facility":"Universitaetsklinikum Jena, Mukoviszidose-Zentrum","city":"Jena","country":"Germany","geoPoint":{"lat":50.92878,"lon":11.5899}},{"facility":"Universitaetsklinkum Koeln, CF-Studienzentrum","city":"Koeln","country":"Germany","geoPoint":{"lat":50.93333,"lon":6.95}},{"facility":"Johannes Gutenberg-Universitaet","city":"Mainz","country":"Germany","geoPoint":{"lat":49.98419,"lon":8.2791}},{"facility":"Pneumologisches Studienzentrum Muenchen-West","city":"Muenchen","country":"Germany","geoPoint":{"lat":51.60698,"lon":13.31243}},{"facility":"Dr. von Haunersches Kinderspital","city":"München","country":"Germany","geoPoint":{"lat":48.13743,"lon":11.57549}},{"facility":"Klinikum Innenstadt, University of Munich","city":"München","country":"Germany","geoPoint":{"lat":48.13743,"lon":11.57549}},{"facility":"Klinik fur Kinder- und Jugendmedizin, Universitatsklinikum Munster","city":"Münster","country":"Germany","geoPoint":{"lat":51.96236,"lon":7.62571}},{"facility":"Klinikum Westbrandenburg (CF)","city":"Potsdam","country":"Germany","geoPoint":{"lat":52.39886,"lon":13.06566}},{"facility":"Universitätsklinikum Tübingen Klinik für Kinder- und Jugendmedizin","city":"Tuebingen","country":"Germany","geoPoint":{"lat":48.52266,"lon":9.05222}},{"facility":"Universitätsklinikum Ulm, Klinik für Kinder- und Jugendmedizin (CF)","city":"Ulm","country":"Germany","geoPoint":{"lat":48.39841,"lon":9.99155}},{"facility":"Universitätsklinikum Würzburg","city":"Würzburg","country":"Germany","geoPoint":{"lat":49.79391,"lon":9.95121}},{"facility":"National Koranyi Institute for TBC and Pulmonology","city":"Budapest","country":"Hungary","geoPoint":{"lat":47.49801,"lon":19.03991}},{"facility":"Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona","city":"Ancona","country":"Italy","geoPoint":{"lat":43.5942,"lon":13.50337}},{"facility":"Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer","city":"Firenze","country":"Italy","geoPoint":{"lat":43.77925,"lon":11.24626}},{"facility":"IRCCS Istituto Giannina Gaslini-Ospedale Pediatrico","city":"Genova","country":"Italy","geoPoint":{"lat":44.40478,"lon":8.94438}},{"facility":"Azienda Ospedaliera Universitaria Policlinico G. Martino","city":"Messina","country":"Italy","geoPoint":{"lat":38.19394,"lon":15.55256}},{"facility":"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico","city":"Milano","country":"Italy","geoPoint":{"lat":45.46427,"lon":9.18951}},{"facility":"Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena","city":"Milan","country":"Italy","geoPoint":{"lat":45.46427,"lon":9.18951}},{"facility":"Azienda Ospedaliera Universitaria Federico II (Adults)","city":"Naples","country":"Italy","geoPoint":{"lat":40.85216,"lon":14.26811}},{"facility":"Malattie Apparato Respiratorio 2 - Centro Fibrosi Cistica","city":"Orbassano","country":"Italy","geoPoint":{"lat":45.00547,"lon":7.53813}},{"facility":"Centro Regionale Fibrosi Cistica, A.O. Ospedale San Carlo","city":"Potenza","country":"Italy","geoPoint":{"lat":40.64175,"lon":15.80794}},{"facility":"Ospedale Pediatrico Bambino Gesu","city":"Rome","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"Azienda Ospedaliera di Verona - Ospedale Civile Maggiore","city":"Verona","country":"Italy","geoPoint":{"lat":45.4299,"lon":10.98444}},{"facility":"Academisch Medisch Centrum (Academic Medical Centre)","city":"Amsterdam","country":"Netherlands","geoPoint":{"lat":52.37403,"lon":4.88969}},{"facility":"HagaZiekenhuis van den Haag","city":"Den Haag","country":"Netherlands","geoPoint":{"lat":52.07667,"lon":4.29861}},{"facility":"UMC St. Radboud","city":"Nijmegen","country":"Netherlands","geoPoint":{"lat":51.8425,"lon":5.85278}},{"facility":"Erasmus Medical Center","city":"Rotterdam","country":"Netherlands","geoPoint":{"lat":51.9225,"lon":4.47917}},{"facility":"Universitair Medisch Centrum Utrecht","city":"Utrecht","country":"Netherlands","geoPoint":{"lat":52.09083,"lon":5.12222}},{"facility":"Oslo University Hospital, Department of Paediatric Medicine","city":"Oslo","country":"Norway","geoPoint":{"lat":59.91273,"lon":10.74609}},{"facility":"Pediatric Hospital Polanki named of Maciej Płażyński","city":"Gdańsk","country":"Poland","geoPoint":{"lat":54.35205,"lon":18.64637}},{"facility":"Institute of Tuberculosis and Lung Diseases","city":"Rabka-Zdrój","country":"Poland","geoPoint":{"lat":49.60889,"lon":19.96654}},{"facility":"Instytut Matki i Dziecka, Klinika Mukowiscydozy IMiD, Oddział Chorób Płuc SZPZOZ im.Dzieci Warszawy w Dziekanowie Leśnym","city":"Łomianki","country":"Poland","geoPoint":{"lat":52.33413,"lon":20.88602}},{"facility":"Hospital de Santa Maria","city":"Lisbon","country":"Portugal","geoPoint":{"lat":38.71667,"lon":-9.13333}},{"facility":"Hospital Sao Joao","city":"Porto","country":"Portugal","geoPoint":{"lat":41.14961,"lon":-8.61099}},{"facility":"Hospital de Cruces","city":"Barakaldo","country":"Spain","geoPoint":{"lat":43.29639,"lon":-2.98813}},{"facility":"Hospital Saint Joan de Deu","city":"Barcelona","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitari Vall d Hebron","city":"Barcelona","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitari Vall d´Hebron Servicio de Broncoscopia","city":"Barcelona","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitario de Jerez de la Frontera","city":"Jerez De La Frontera","country":"Spain","geoPoint":{"lat":36.68645,"lon":-6.13606}},{"facility":"Hospital Infantil Universitario Nino Jesus","city":"Madrid","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario 12 de Octubre","city":"Madrid","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario Infantil La Paz","city":"Madrid","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario Ramon y Cajal","city":"Madrid","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Virgen de la Arrixaca","city":"Murcia","country":"Spain","geoPoint":{"lat":37.98704,"lon":-1.13004}},{"facility":"Corporacio Sanitaria Parc Tauli - Sabadell Hospital Universitari","city":"Sabadell","country":"Spain","geoPoint":{"lat":41.54329,"lon":2.10942}},{"facility":"Hospital Universitario Virgen del Rocio","city":"Sevilla","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Hospital Universitario y Politecnico La Fe","city":"Valencia","country":"Spain","geoPoint":{"lat":39.46975,"lon":-0.37739}},{"facility":"Sahlgrenska Universitetssjukhuset","city":"Göteborg","country":"Sweden","geoPoint":{"lat":57.70716,"lon":11.96679}},{"facility":"Karolinska Universitetssjukhuset, Huddinge","city":"Stockholm","country":"Sweden","geoPoint":{"lat":59.33258,"lon":18.0649}},{"facility":"Kinderspital Zuerich","city":"Zurich","country":"Switzerland","geoPoint":{"lat":47.36667,"lon":8.54999}}]},"ipdSharingStatementModule":{"ipdSharing":"NO","description":"Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing"}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"This study was conducted in cystic fibrosis (CF) participants aged 6 years and older with a non-F508del ELX/TEZ/IVA-responsive cystic fibrosis transmembrane conductance regulator gene (CFTR) mutation.","groups":[{"id":"FG000","title":"Placebo","description":"Participants received placebo matched to ELX/TEZ/IVA FDC in the morning and placebo matched to IVA in the evening for 24 weeks."},{"id":"FG001","title":"ELX/TEZ/IVA","description":"Participants 6 to less than (\\<) 12 years of age and weighing \\<30 kilogram (kg) at Day 1 received ELX 100 milligram (mg)/TEZ 50 mg /IVA 75 mg as fixed dose combination (FDC) tablets in the morning and IVA as mono tablet in the evening and those weighing more than or equal to (≥) 30 kg at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks. Participants ≥12 years age at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"102"},{"groupId":"FG001","numSubjects":"205"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"102"},{"groupId":"FG001","numSubjects":"197"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"8"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Withdrawal of consent (not due to AE)","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All participants who received at least one dose of the study drug were included in the baseline analysis.","groups":[{"id":"BG000","title":"Placebo","description":"Participants received placebo matched to ELX/TEZ/IVA FDC in the morning and placebo matched to IVA in the evening for 24 weeks."},{"id":"BG001","title":"ELX/TEZ/IVA","description":"Participants 6 to \\<12 years of age and weighing \\<30kg at Day 1 received ELX 100 mg/TEZ 50 mg /IVA 75 mg as FDC tablets in the morning and IVA as mono tablet in the evening and those weighing ≥30 kg at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks. Participants ≥12 years age at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"102"},{"groupId":"BG001","value":"205"},{"groupId":"BG002","value":"307"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"33.9","spread":"16.4"},{"groupId":"BG001","value":"33.3","spread":"15.9"},{"groupId":"BG002","value":"33.5","spread":"16.0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"52"},{"groupId":"BG001","value":"113"},{"groupId":"BG002","value":"165"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"50"},{"groupId":"BG001","value":"92"},{"groupId":"BG002","value":"142"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"Hispanic or Latino","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"11"}]}]},{"title":"Not Hispanic or Latino","categories":[{"measurements":[{"groupId":"BG000","value":"88"},{"groupId":"BG001","value":"171"},{"groupId":"BG002","value":"259"}]}]},{"title":"Not Collected per Local Regulations","categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"37"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"86"},{"groupId":"BG001","value":"172"},{"groupId":"BG002","value":"258"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"6"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"}]}]},{"title":"Not Collected per Local Regulations","categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"38"}]}]},{"title":"White, Asian","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)","description":"FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"percent predicted FEV1","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"68.1","spread":"18.1"},{"groupId":"BG001","value":"67.5","spread":"17.6"},{"groupId":"BG002","value":"67.7","spread":"17.7"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)","description":"FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.","populationDescription":"The Full Analysis Set (FAS) will include all randomized participants who carry the intended mutation and received at least 1 dose of study drug. Here \"Overall Number of Participants Analyzed\" signifies those participants who were evaluated for this outcome measure.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"percent predicted FEV1","timeFrame":"From Baseline Through Week 24","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to ELX/TEZ/IVA FDC in the morning and placebo matched to IVA in the evening for 24 weeks."},{"id":"OG001","title":"ELX/TEZ/IVA","description":"Participants 6 to \\<12 years of age and weighing \\<30kg at Day 1 received ELX 100 mg/TEZ 50 mg /IVA 75 mg as FDC tablets in the morning and IVA as mono tablet in the evening and those weighing ≥30 kg at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks. Participants ≥12 years age at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"192"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","lowerLimit":"-2.0","upperLimit":"1.3"},{"groupId":"OG001","value":"8.9","lowerLimit":"7.7","upperLimit":"10.0"}]}]}],"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"< 0.0001","statisticalMethod":"Mixed Models for Repeated Measures","paramType":"LS Mean difference","paramValue":"9.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"7.2","ciUpperLimit":"11.3"}]},{"type":"SECONDARY","title":"Absolute Change in Sweat Chloride (SwCl)","description":"Sweat samples were collected using an approved collection device.","populationDescription":"FAS. Here \"Overall Number of Participants Analyzed\" signifies those participants who were evaluated for this outcome measure.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"millimole per liter (mmol/L)","timeFrame":"From Baseline Through Week 24","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to ELX/TEZ/IVA FDC in the morning and placebo matched to IVA in the evening for 24 weeks."},{"id":"OG001","title":"ELX/TEZ/IVA","description":"Participants 6 to \\<12 years of age and weighing \\<30kg at Day 1 received ELX 100 mg/TEZ 50 mg /IVA 75 mg as FDC tablets in the morning and IVA as mono tablet in the evening and those weighing ≥30 kg at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks. Participants ≥12 years age at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"200"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"-2.6","upperLimit":"3.6"},{"groupId":"OG001","value":"-27.8","lowerLimit":"-30.0","upperLimit":"-25.6"}]}]}],"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"< 0.0001","statisticalMethod":"Mixed Models for Repeated Measures","paramType":"LS Mean difference","paramValue":"-28.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-32.1","ciUpperLimit":"-24.5"}]},{"type":"SECONDARY","title":"Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain (RD) Score","description":"The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.","populationDescription":"FAS. Here \"Overall Number of Participants Analyzed\" signifies those participants who were evaluated for this outcome measure.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"units on a scale","timeFrame":"From Baseline Through Week 24","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to ELX/TEZ/IVA FDC in the morning and placebo matched to IVA in the evening for 24 weeks."},{"id":"OG001","title":"ELX/TEZ/IVA","description":"Participants 6 to \\<12 years of age and weighing \\<30kg at Day 1 received ELX 100 mg/TEZ 50 mg /IVA 75 mg as FDC tablets in the morning and IVA as mono tablet in the evening and those weighing ≥30 kg at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks. Participants ≥12 years age at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"202"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","lowerLimit":"-5.2","upperLimit":"1.3"},{"groupId":"OG001","value":"17.5","lowerLimit":"15.2","upperLimit":"19.8"}]}]}],"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"< 0.0001","statisticalMethod":"Mixed Models for Repeated Measures","paramType":"LS Mean difference","paramValue":"19.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"15.5","ciUpperLimit":"23.5"}]},{"type":"SECONDARY","title":"Absolute Change in Body Mass Index (BMI)","description":"BMI was defined as weight in kilogram (kg) divided by height in square meter (m\\^2).","populationDescription":"FAS. Here \"Overall Number of Participants Analyzed\" signifies those participants who were evaluated for this outcome measure.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"kg/m^2","timeFrame":"From Baseline at Week 24","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to ELX/TEZ/IVA FDC in the morning and placebo matched to IVA in the evening for 24 weeks."},{"id":"OG001","title":"ELX/TEZ/IVA","description":"Participants 6 to \\<12 years of age and weighing \\<30kg at Day 1 received ELX 100 mg/TEZ 50 mg /IVA 75 mg as FDC tablets in the morning and IVA as mono tablet in the evening and those weighing ≥30 kg at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks. Participants ≥12 years age at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"196"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","lowerLimit":"0.16","upperLimit":"0.53"},{"groupId":"OG001","value":"0.81","lowerLimit":"0.68","upperLimit":"0.94"}]}]}],"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"< 0.0001","statisticalMethod":"Mixed Models for Repeated Measures","paramType":"LS Mean difference","paramValue":"0.47","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.24","ciUpperLimit":"0.69"}]},{"type":"SECONDARY","title":"Absolute Change in Weight","populationDescription":"FAS. Here \"Overall Number of Participants Analyzed\" signifies those participants who were evaluated for this outcome measure.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"kilogram (kg)","timeFrame":"From Baseline at Week 24","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to ELX/TEZ/IVA FDC in the morning and placebo matched to IVA in the evening for 24 weeks."},{"id":"OG001","title":"ELX/TEZ/IVA","description":"Participants 6 to \\<12 years of age and weighing \\<30kg at Day 1 received ELX 100 mg/TEZ 50 mg /IVA 75 mg as FDC tablets in the morning and IVA as mono tablet in the evening and those weighing ≥30 kg at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks. Participants ≥12 years age at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"196"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","lowerLimit":"0.6","upperLimit":"1.7"},{"groupId":"OG001","value":"2.4","lowerLimit":"2.1","upperLimit":"2.8"}]}]}],"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"< 0.0001","statisticalMethod":"Mixed Models for Repeated Measures","paramType":"LS Mean difference","paramValue":"1.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.6","ciUpperLimit":"1.9"}]},{"type":"SECONDARY","title":"Number of Pulmonary Exacerbations (PEx)","description":"Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.","populationDescription":"FAS. Here \"Overall Number of Participants Analyzed\" signifies those participants who were evaluated for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"PEx events","timeFrame":"From Baseline Through Week 24","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to ELX/TEZ/IVA FDC in the morning and placebo matched to IVA in the evening for 24 weeks."},{"id":"OG001","title":"ELX/TEZ/IVA","description":"Participants 6 to \\<12 years of age and weighing \\<30kg at Day 1 received ELX 100 mg/TEZ 50 mg /IVA 75 mg as FDC tablets in the morning and IVA as mono tablet in the evening and those weighing ≥30 kg at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks. Participants ≥12 years age at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"205"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"21"}]}]}]},{"type":"SECONDARY","title":"Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","populationDescription":"Safety Set was defined as all participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 up to Week 28","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo matched to ELX/TEZ/IVA FDC in the morning and placebo matched to IVA in the evening for 24 weeks."},{"id":"OG001","title":"ELX/TEZ/IVA","description":"Participants 6 to \\<12 years of age and weighing \\<30 kg at Day 1 received ELX 100mg/TEZ 50 mg /IVA 75 mg as FDC tablets in the morning and IVA as mono tablet in the evening and those weighing ≥30 kg at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks. Participants ≥12 years age at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"205"}]}],"classes":[{"title":"Participants with TEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"193"}]}]},{"title":"Participants with SAEs","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"18"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Day 1 up to Week 28","description":"Safety Set was defined as all participants who received at least 1 dose of study drug.","eventGroups":[{"id":"EG000","title":"Placebo","description":"Participants received placebo matched to ELX/TEZ/IVA FDC in the morning and placebo matched to IVA in the evening for 24 weeks.","deathsNumAffected":0,"deathsNumAtRisk":102,"seriousNumAffected":15,"seriousNumAtRisk":102,"otherNumAffected":86,"otherNumAtRisk":102},{"id":"EG001","title":"ELX/TEZ/IVA","description":"Participants 6 to \\<12 years of age and weighing \\<30 kg at Day 1 received ELX 100mg/TEZ 50 mg /IVA 75 mg as FDC tablets in the morning and IVA as mono tablet in the evening and those weighing ≥30 kg at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks. Participants ≥12 years age at Day 1 received ELX 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA as mono tablet in the evening for 24 weeks.","deathsNumAffected":1,"deathsNumAtRisk":205,"seriousNumAffected":18,"seriousNumAtRisk":205,"otherNumAffected":164,"otherNumAtRisk":205}],"seriousEvents":[{"term":"Stress cardiomyopathy","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":102},{"groupId":"EG001","numAffected":0,"numAtRisk":205}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":102},{"groupId":"EG001","numAffected":1,"numAtRisk":205}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":102},{"groupId":"EG001","numAffected":1,"numAtRisk":205}]},{"term":"Subileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":102},{"groupId":"EG001","numAffected":1,"numAtRisk":205}]},{"term":"Drug intolerance","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":102},{"groupId":"EG001","numAffected":0,"numAtRisk":205}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":102},{"groupId":"EG001","numAffected":1,"numAtRisk":205}]},{"term":"Bronchopulmonary aspergillosis allergic","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":102},{"groupId":"EG001","numAffected":2,"numAtRisk":205}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":102},{"groupId":"EG001","numAffected":1,"numAtRisk":205}]},{"term":"Hepatitis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":102},{"groupId":"EG001","numAffected":1,"numAtRisk":205}]},{"term":"Infective pulmonary exacerbation of cystic fibrosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":102},{"groupId":"EG001","numAffected":5,"numAtRisk":205}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":102},{"groupId":"EG001","numAffected":1,"numAtRisk":205}]},{"term":"Pseudomonas infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":102},{"groupId":"EG001","numAffected":1,"numAtRisk":205}]},{"term":"Vestibular neuronitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":102},{"groupId":"EG001","numAffected":1,"numAtRisk":205}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":102},{"groupId":"EG001","numAffected":1,"numAtRisk":205}]},{"term":"Polyarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":102},{"groupId":"EG001","numAffected":1,"numAtRisk":205}]},{"term":"Lung adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":102},{"groupId":"EG001","numAffected":1,"numAtRisk":205}]},{"term":"Anxiety disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":102},{"groupId":"EG001","numAffected":1,"numAtRisk":205}]},{"term":"Post-traumatic stress disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":102},{"groupId":"EG001","numAffected":1,"numAtRisk":205}]},{"term":"Renal colic","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":102},{"groupId":"EG001","numAffected":0,"numAtRisk":205}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":102},{"groupId":"EG001","numAffected":1,"numAtRisk":205}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":102},{"groupId":"EG001","numAffected":1,"numAtRisk":205}]}],"otherEvents":[{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":102},{"groupId":"EG001","numAffected":17,"numAtRisk":205}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":102},{"groupId":"EG001","numAffected":10,"numAtRisk":205}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":102},{"groupId":"EG001","numAffected":15,"numAtRisk":205}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":102},{"groupId":"EG001","numAffected":26,"numAtRisk":205}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":102},{"groupId":"EG001","numAffected":15,"numAtRisk":205}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":102},{"groupId":"EG001","numAffected":27,"numAtRisk":205}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":102},{"groupId":"EG001","numAffected":19,"numAtRisk":205}]},{"term":"Infective pulmonary exacerbation of cystic fibrosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":36,"numAtRisk":102},{"groupId":"EG001","numAffected":28,"numAtRisk":205}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":102},{"groupId":"EG001","numAffected":18,"numAtRisk":205}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":102},{"groupId":"EG001","numAffected":42,"numAtRisk":205}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":102},{"groupId":"EG001","numAffected":20,"numAtRisk":205}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":102},{"groupId":"EG001","numAffected":17,"numAtRisk":205}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":102},{"groupId":"EG001","numAffected":37,"numAtRisk":205}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":102},{"groupId":"EG001","numAffected":36,"numAtRisk":205}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":102},{"groupId":"EG001","numAffected":12,"numAtRisk":205}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":102},{"groupId":"EG001","numAffected":6,"numAtRisk":205}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":102},{"groupId":"EG001","numAffected":17,"numAtRisk":205}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":102},{"groupId":"EG001","numAffected":6,"numAtRisk":205}]},{"term":"Sputum increased","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":102},{"groupId":"EG001","numAffected":20,"numAtRisk":205}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":102},{"groupId":"EG001","numAffected":45,"numAtRisk":205}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":true},"pointOfContact":{"title":"Medical Monitor","organization":"Vertex Pharmaceuticals Incorporated","email":"medicalinfo@vrtx.com","phone":"617-341-6777"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2022-04-21","uploadDate":"2024-07-02T01:34","filename":"Prot_000.pdf","size":6223870},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2023-06-08","uploadDate":"2024-07-02T01:36","filename":"SAP_001.pdf","size":5205134}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-04-09","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2024-07-31","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D003550","term":"Cystic Fibrosis"},{"id":"D005355","term":"Fibrosis"}],"ancestors":[{"id":"D010335","term":"Pathologic Processes"},{"id":"D010182","term":"Pancreatic Diseases"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D030342","term":"Genetic Diseases, Inborn"},{"id":"D007232","term":"Infant, Newborn, Diseases"}],"browseLeaves":[{"id":"M8485","name":"Fibrosis","asFound":"Fibrosis","relevance":"HIGH"},{"id":"M6755","name":"Cystic Fibrosis","asFound":"Cystic Fibrosis","relevance":"HIGH"},{"id":"M13102","name":"Pancreatic Diseases","relevance":"LOW"},{"id":"M8883","name":"Gastrointestinal Diseases","relevance":"LOW"},{"id":"M7255","name":"Digestive System Diseases","relevance":"LOW"},{"id":"M11168","name":"Lung Diseases","relevance":"LOW"},{"id":"M14977","name":"Respiratory Tract Diseases","relevance":"LOW"},{"id":"M23686","name":"Genetic Diseases, Inborn","relevance":"LOW"},{"id":"M10276","name":"Infant, Newborn, Diseases","relevance":"LOW"},{"id":"T1710","name":"Cystic Fibrosis","asFound":"Cystic Fibrosis","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC06","name":"Digestive System Diseases"},{"abbrev":"BC08","name":"Respiratory Tract (Lung and Bronchial) Diseases"},{"abbrev":"BC16","name":"Diseases and Abnormalities at or Before Birth"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C545203","term":"Ivacaftor"},{"id":"C000629074","term":"Elexacaftor"}],"ancestors":[{"id":"D065101","term":"Chloride Channel Agonists"},{"id":"D049990","term":"Membrane Transport Modulators"},{"id":"D045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M250281","name":"Ivacaftor","asFound":"Dextrose","relevance":"HIGH"},{"id":"M76784","name":"Elexacaftor","asFound":"Morning after","relevance":"HIGH"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":true}
